PF-05085727
PF-05085727 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | DMSO：62.5 mg/mL（151.19 mM；需要超声波） |
| 形态 | 固体 |
| 颜色 | 白色至黄色 |
| InChIKey | SHAVEYUXRBIMLA-UHFFFAOYSA-N |
| SMILES | CN(N=C1)C(C2=CC=C(C(F)(F)F)C=C2)=C1C3=NN(C)C4=C3C(N5CCC5)=NC=N4 |
PF-05085727 用途与合成方法
|
PDE2A 2 nM (IC 50 ) |
PF-05085727 shows weak activity with IC 50 of 162 μM to induce cell death in a cellular toxicity assay using transformed human liver endothelial (THLE) cells.PF-05085727 (3 μM) shows a minimal inhibition of cytochrome P450 enzymes (CYPs), inhibits 1A2, 2C8, 2C9, 2D6 and 3A4 with percentage% of 16%, 18%, 7%, 4%, and 30%, respectively.PF-05085727 (10 μM) inhibits PDE1B, PDE4B, PDE7B and PDE10A with IC 50 values of 12.146 μM, 22,503 μM, 13.157 μM and 6.515 μM, respectively.
PF-05085727 (subcutaneous injection; 3.2 mg/kg/mice; 3 mg/kg/rat) gives a ratio of unbound brain (C bu ) to unbound plasma (C pu ) of ca. 0.27 and 0.37, respectively.PF-05085727 in mice leads to an acute and exposure-dependent elevation in the accumulation of bulk levels of cGMP in cortex, striatum, and hippocampus as measured by enzyme-linked immunosorbent assay.
PF-05085727 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-102050 | PF-05085727 | 1415637-72-7 | 5mg | 800 |
| 2026-09-15 | HY-102050 | PF-05085727 | 1415637-72-7 | 10mM * 1mLin DMSO | 880 |
